Born on the 2nd of September 1969, Eric Lefkofsky is an entrepreneur from the United States of America. He spent his childhood in Michigan and attended Southfield-Lathrup High school and later graduated from University of Michigan in 1991 with honors. He then continued with law studies at the same university and graduated in 1993.
Brief Entrepreneurial History
Eric began his entrepreneurial life as a carpet seller in University of Michigan. It was after his graduation from law school that Eric Lefkofsky and his college friend started up their first company. This made the debut of the founding of his many businesses Eric Lefkofsky is one of the co-founders and also the chief executive officer (CEO) of Tempus. In addition to this, he also happens to among the co-founders of Groupon, Echo Global Logistics and also Lightbank, which a Chicago-based capital firm.
Tempus is a technology-based company which has built an OS (Operating system) to help battle cancer. He quit his chief executive officer role at Groupon so that he could work on Tempus. This is a health technology startup that is building infrastructure to help bring up to date cancer treatment. The role of the company is to assist doctors and other healthcare specialists to come up with real-time, data-driven and individualized patient treatment and management decisions after the analysis of the given patient’s genetic code.Eric Lefkofsky partnered with Brad Keywell in initiating Tempus. Eric and Brad have a lot in common. There are so many businesses they run together. They always spend quality time identifying solutions for problems they might be experiencing. Their corporate duty in determining viable remedies for problems affecting them has taken them a long way in impacting societies.
Eric’s Philanthropic Activities
Lefkofsky Family Foundation is a private philanthropic foundation which was established by Eric Lefkofsky and his wife in 2006. The foundation was created so as to aid in the advancement of high-impact projects which usually enhance the lives of the people in the communities that they serve. It is through this foundation that Lefkofsky and his wife have been able to give regular donations to cancer research centers and causes. At Lurie Children’s Hospital in Chicago, Lefkofsky is also a trustee.
One of the outstanding characters that Clay Siegall has shown with remarkable consistence over the years is his commitment and strong conviction towards finding a better alternative treatment for cancer. While drawing inspiration from early personal experience with cancer, Dr. Clay Siegall has used his experience as a company executive, entrepreneur, research scientist and scholar to lead the research and development for innovative and technology-based alternative cancer therapies that are more effective and cause less pain to the patients compared to conventional treatment options.
Such strong commitment and dedication towards his duties as the cofounder and chief executive officer at Seattle Genetics has seen him guide the company towards operational and financial success despite significant challenges. Despite taking significantly long to generate profits, Dr. Siegall had strong faith in the company’s legal and sales teams, which have played critical roles in the company’s ability to finally realize financial success ten years after its initial public offer (IPO). He has also guided the company towards strategic partnerships with several key industry players including Bayer and Pfizer. These partnerships have been crucial in the success of the company’s research efforts towards developing an effective conjugate therapy for treatment of cancer. Clay Siegall believes that strong focus and intense passion for the task at hand is the primary key to success.
Commitment to Cancer Community
Clay Siegall is a remarkable company executive who has dedicated his professional career, education and company resources towards alleviating the pain cancer patients and their families go through. His interest in cancer and related fields began at the University of Maryland where he graduated with a Bachelor of Science in Zoology. He later specialized in genetics for his Doctor of Philosophy degree studies at George Washington University. His scholarly endeavors in the subject has also seen author several papers on the topic while also working for several organizations specializing in cancer research. This is in addition to the 15 patents to his name and over one billion dollars raised towards effective and innovative cancer therapies and drugs development and research. Currently, the company is on the verge on adding over a dozen new targeted treatment drugs to Adcentris, which has already been approved by the FDA.